PJSC Farmak pharmaceutical company (Kyiv) will use the German scientists’ protocol of clinical trials of the antiviral medicine efficiency, produced by Farmak for coronavirus (COVID-19) treatment, the company’s press service said with reference to Chairperson of the Supervisory Board of Farmak Filya Zhebrovska.
“This medicine was tested apart from human trials and showed good results. We need to come to clinical trials and conduct them, so that in the autumn we know that this medicine is effective and it can fight COVID-19. German scientists helped us indeed. They have prepared the clinical trial protocol correctly, so that we can investigate if this medicine is working according to all necessary criteria. This is a big, hard and expensive work,” she said.
Zhebrovska said that the antiviral medicine, which efficiency against COVID-19 Farmak plans to test, is also being studied by foreign research centers.
“There are good studies on our antiviral medicine at Oxford and Frankfurt universities,” she said.
Zhebrovska said that significant financial funds are needed for the development of COVID-19 vaccines, which Ukraine and the Ukrainian pharmaceutical companies do not currently have.
“The European Investment Bank organized a consortium together with the WHO and allocated EUR 7.6 billion for the development of vaccines for COVID-19. Neither Farmak, nor Ukraine, unfortunately, have such financial capacities. Perhaps we can join to these works at some stage,” she said.
Farmak is the leader in the pharmaceutical market of Ukraine in terms of sales. It exports products to 20 countries.
